Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Author:
Publisher
MDPI AG
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Link
http://www.mdpi.com/1424-8247/8/1/1/pdf
Reference95 articles.
1. Cancer statistics, 2014
2. Cancer treatment and survivorship statistics, 2012
3. Improved survival in multiple myeloma and the impact of novel therapies
4. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
5. NCCN Guidelines Version 2.2014 Multiple Myeloma;Raje,2013
Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent Advances in Multiple myeloma;Biomedical and Pharmacology Journal;2024-03-20
2. The proteasome modulates endocytosis specifically in glomerular cells to promote kidney filtration;Nature Communications;2024-03-01
3. Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome;Frontiers in Chemistry;2024-01-08
4. Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification;European Journal of Medicinal Chemistry;2023-12
5. Review of Patents for Anticancer Agents Targeting Adenosine Monophosphate-Activated Protein Kinase;Journal of Medicinal Food;2023-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3